European commission approves label expansion of Pepaxti to third-line treatment
Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announced that the European Commission (EC) has formally approved the Type II variation application for Pepaxti (melflufen).
Read original article on The Medical News →Related news
-
A weight-loss drug eased knee arthritis pain in two major trials
United Kingdom
-
Brain's 'cleanup' molecule could aid recovery after stroke
United Kingdom
-
Blood proteins that may predict brain and cardiovascular health issues identified
United Kingdom
-
Researchers detect signs of neuronal damage in the earliest stage of Huntington's disease
United Kingdom
-
Patient comfort with AI-driven health care hinges on provider oversight
United Kingdom
-
Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory
United Kingdom
-
Gas prices dip below $4 but inflation remains stubbornly high
United States
-
Martian Volcanic Discovery Could Be ‘Smoking Gun’ in Search for Life
United Kingdom